In support of this, recent observation of novel class of glucose-lowering agents—inhibitors of SGLT2—known to improve insulin sensitivity by inhibiting glucose re-absorption in the kidney, shown to be effective not only in patients with type 2 diabetes but also in type 1 diabetes48 and associated with reduced CKD in non-diabetic population49. Here, SLC5A2 is linked to chronic kidney disease.